[
  {
    "ts": null,
    "headline": "3 Drug Stocks to Buy at a Discount",
    "summary": "The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.",
    "url": "https://finnhub.io/api/news?id=9fcdcc39ce0addd277b2951b739d1aac0fe758a8e69a9b299ea726657eeba350",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767820800,
      "headline": "3 Drug Stocks to Buy at a Discount",
      "id": 138033031,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.",
      "url": "https://finnhub.io/api/news?id=9fcdcc39ce0addd277b2951b739d1aac0fe758a8e69a9b299ea726657eeba350"
    }
  },
  {
    "ts": null,
    "headline": "The Dow Is Cruising Past Milestones. What Comes After 50,000.",
    "summary": "The Dow Jones Industrial Average is on the verge of another big milestone and could continue to climb as the rally broadens.",
    "url": "https://finnhub.io/api/news?id=2c397c3ece6f139d071a5da726d71c7b7b4b3be02a2f027079c983b3bd1cc5da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767803640,
      "headline": "The Dow Is Cruising Past Milestones. What Comes After 50,000.",
      "id": 138033060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Dow Jones Industrial Average is on the verge of another big milestone and could continue to climb as the rally broadens.",
      "url": "https://finnhub.io/api/news?id=2c397c3ece6f139d071a5da726d71c7b7b4b3be02a2f027079c983b3bd1cc5da"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
    "url": "https://finnhub.io/api/news?id=a62cccc070b9a396cca61f6811501228f9a40c44202c49e42f114ff24efc44bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767794405,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 138027172,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
      "url": "https://finnhub.io/api/news?id=a62cccc070b9a396cca61f6811501228f9a40c44202c49e42f114ff24efc44bc"
    }
  },
  {
    "ts": null,
    "headline": "Bank of America Out With Q1 2026 Top US Ideas Dividend Picks",
    "summary": "These top BofA Securities stock picks are perfect for growth and income investors seeking dependable passive income from reliable companies.",
    "url": "https://finnhub.io/api/news?id=76600c826dad62a2cb8913e545d15fb53e21f44ba444cf90b0b6bca1273c0fc0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767792014,
      "headline": "Bank of America Out With Q1 2026 Top US Ideas Dividend Picks",
      "id": 138027124,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "These top BofA Securities stock picks are perfect for growth and income investors seeking dependable passive income from reliable companies.",
      "url": "https://finnhub.io/api/news?id=76600c826dad62a2cb8913e545d15fb53e21f44ba444cf90b0b6bca1273c0fc0"
    }
  },
  {
    "ts": null,
    "headline": "Merck Begins Phase 3 Trial of Calderasib With Keytruda QLEX in Non-Small Cell Lung Cancer",
    "summary": "Merck (MRK) said Wednesday it has initiated a phase 3 clinical trial to evaluate calderasib combined",
    "url": "https://finnhub.io/api/news?id=27e2f7d910a146caba21b46187b5b279ef4dfeadde74ab6c3276cfa85d319b62",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767790103,
      "headline": "Merck Begins Phase 3 Trial of Calderasib With Keytruda QLEX in Non-Small Cell Lung Cancer",
      "id": 138027174,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) said Wednesday it has initiated a phase 3 clinical trial to evaluate calderasib combined",
      "url": "https://finnhub.io/api/news?id=27e2f7d910a146caba21b46187b5b279ef4dfeadde74ab6c3276cfa85d319b62"
    }
  },
  {
    "ts": null,
    "headline": "Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC",
    "summary": "RAHWAY, N.J., January 07, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a Phase 3 clinical trial evaluating calderasib (MK-1084), an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) for the first-line treatment of patients with KRAS G12C-mutant, advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).",
    "url": "https://finnhub.io/api/news?id=e60328cc34c96cec76846c7fcf9a6d4fe2c8ed08576fbb293558ac3eb45ab213",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767786600,
      "headline": "Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC",
      "id": 138025856,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., January 07, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a Phase 3 clinical trial evaluating calderasib (MK-1084), an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) for the first-line treatment of patients with KRAS G12C-mutant, advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).",
      "url": "https://finnhub.io/api/news?id=e60328cc34c96cec76846c7fcf9a6d4fe2c8ed08576fbb293558ac3eb45ab213"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Complete Acquisition of Cidara Therapeutics",
    "summary": "RAHWAY, N.J., January 07, 2026--Merck to Complete Acquisition of Cidara Therapeutics",
    "url": "https://finnhub.io/api/news?id=59a9c81a05b0e6f1c36498c42fab4023ce99f389749c742a04b9f0166d836ea8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767786300,
      "headline": "Merck to Complete Acquisition of Cidara Therapeutics",
      "id": 138025857,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., January 07, 2026--Merck to Complete Acquisition of Cidara Therapeutics",
      "url": "https://finnhub.io/api/news?id=59a9c81a05b0e6f1c36498c42fab4023ce99f389749c742a04b9f0166d836ea8"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3",
    "summary": "RAHWAY, N.J., January 07, 2026--Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3",
    "url": "https://finnhub.io/api/news?id=eb48d53586538a9a5aa8a9946c6bc84c38af4d0e7937f5a2931c09aecf88035d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767785400,
      "headline": "Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3",
      "id": 138025858,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., January 07, 2026--Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3",
      "url": "https://finnhub.io/api/news?id=eb48d53586538a9a5aa8a9946c6bc84c38af4d0e7937f5a2931c09aecf88035d"
    }
  },
  {
    "ts": null,
    "headline": "Quant Q&A With Steven Cress",
    "summary": "Seeking Alpha's Head of Quant, Steven Cress, answers your questions!",
    "url": "https://finnhub.io/api/news?id=b803d76c99d6e4c8d5780b1be6003950f35a55319b3ccd006ca515631dfc6e08",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767769200,
      "headline": "Quant Q&A With Steven Cress",
      "id": 138025654,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1097346792/image_1097346792.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Seeking Alpha's Head of Quant, Steven Cress, answers your questions!",
      "url": "https://finnhub.io/api/news?id=b803d76c99d6e4c8d5780b1be6003950f35a55319b3ccd006ca515631dfc6e08"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma race to snap up biotech assets as $170 billion patent cliff looms",
    "summary": "Companies are facing a situation where they need to fill their pipelines, but also navigate a competitive environment for the best assets.",
    "url": "https://finnhub.io/api/news?id=a0c504f9e512dfd1f9c4c0c403aa8efad6e2dd4ab308b1791cfebe567d1454ed",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767753071,
      "headline": "Big Pharma race to snap up biotech assets as $170 billion patent cliff looms",
      "id": 138028004,
      "image": "https://image.cnbcfm.com/api/v1/image/108248856-1767718931887-gettyimages-1417392226-_x3m1126.jpeg?v=1767718937&w=1920&h=1080",
      "related": "MRK",
      "source": "CNBC",
      "summary": "Companies are facing a situation where they need to fill their pipelines, but also navigate a competitive environment for the best assets.",
      "url": "https://finnhub.io/api/news?id=a0c504f9e512dfd1f9c4c0c403aa8efad6e2dd4ab308b1791cfebe567d1454ed"
    }
  }
]